Barclays Raises TruBridge (NASDAQ:TBRG) Price Target to $14.00

TruBridge (NASDAQ:TBRG - Get Free Report) had its price target hoisted by equities research analysts at Barclays from $10.00 to $14.00 in a research note issued to investors on Monday,Benzinga reports. The brokerage currently has an "equal weight" rating on the stock. Barclays's target price points to a potential downside of 2.17% from the stock's current price.

TBRG has been the subject of several other reports. Royal Bank of Canada reaffirmed an "outperform" rating and set a $14.00 price objective on shares of TruBridge in a research note on Tuesday, September 17th. Cantor Fitzgerald reissued an "overweight" rating and issued a $13.00 price target on shares of TruBridge in a research note on Friday, October 4th.

TruBridge Trading Up 5.6 %

Shares of NASDAQ:TBRG traded up $0.76 during midday trading on Monday, hitting $14.31. 168,254 shares of the stock traded hands, compared to its average volume of 150,075. The stock has a market capitalization of $214.08 million, a PE ratio of -3.50, a P/E/G ratio of 3.11 and a beta of 0.61. The business's 50 day moving average is $12.57 and its two-hundred day moving average is $11.17. The company has a quick ratio of 1.76, a current ratio of 1.77 and a debt-to-equity ratio of 0.98. TruBridge has a one year low of $7.55 and a one year high of $14.38.

TruBridge (NASDAQ:TBRG - Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The company reported $0.08 EPS for the quarter, missing the consensus estimate of $0.15 by ($0.07). The firm had revenue of $84.73 million for the quarter, compared to the consensus estimate of $80.71 million. TruBridge had a negative net margin of 17.72% and a positive return on equity of 1.75%. As a group, research analysts forecast that TruBridge will post 0.56 earnings per share for the current year.

Insider Buying and Selling

In related news, major shareholder Pinetree Capital Ltd. purchased 3,997 shares of the firm's stock in a transaction that occurred on Wednesday, October 2nd. The stock was bought at an average cost of $11.93 per share, with a total value of $47,684.21. Following the completion of the purchase, the insider now directly owns 603,997 shares in the company, valued at approximately $7,205,684.21. This represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 3.60% of the stock is owned by insiders.

Institutional Investors Weigh In On TruBridge

Hedge funds and other institutional investors have recently bought and sold shares of the business. GAMMA Investing LLC purchased a new stake in TruBridge in the third quarter worth about $26,000. CacheTech Inc. purchased a new stake in TruBridge in the third quarter worth about $2,875,000. Cubist Systematic Strategies LLC purchased a new stake in TruBridge in the second quarter worth about $740,000. Point72 DIFC Ltd purchased a new stake in TruBridge in the second quarter worth about $56,000. Finally, Williams & Novak LLC purchased a new stake in TruBridge in the third quarter worth about $234,000. Hedge funds and other institutional investors own 88.64% of the company's stock.

TruBridge Company Profile

TruBridge, Inc provides healthcare solutions and services for community hospitals, clinics, and other healthcare systems in the United States and internationally. The company operates in three segments: Revenue Cycle Management (RCM), Electronic Health Record (HER), and Patient Engagement. It focuses on providing RCM solutions for care settings, regardless of primary healthcare information solutions provider along with business management, consulting, managed IT services, and analytics and business intelligence.